Donnerstag, 28. März 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Rekrutierend

NCT-Nummer:
NCT03969004

Studienbeginn:
Juni 2019

Letztes Update:
26.03.2024

Wirkstoff:
Cemiplimab, Placebo

Indikation (Clinical Trials):
Carcinoma, Carcinoma, Squamous Cell

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Regeneron Pharmaceuticals

Collaborator:
Sanofi

Studienleiter

Clinical Trial Management
Study Director
Regeneron Pharmaceuticals

Kontakt

Studienlocations
(3 von 165)

NCT Dermatoonkologie -Hautklinik Heidelberg
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR
55131 Mainz
(Rheinland-Pfalz)
GermanyRekrutierend» Google-Maps
Charite- Universitaetsmedizin Berlin
10117 Berlin
(Berlin)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum der Ruhr Universitaet Bochum (UKRUB), St. Josef Hospital
44791 Bochum
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Elbekliniken Buxtehude
21614 Buxtehude
(Niedersachsen)
GermanyRekrutierend» Google-Maps
University Hospital Dresden
01307 Dresden
(Sachsen)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum Essen (AoR)
45147 Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
SLK-Kliniken Heilbronn GmbH
74078 Heilbronn
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum Schleswig-Holstein, Campus Kiel
24105 Kiel
(Schleswig-Holstein)
GermanyRekrutierend» Google-Maps
Klinikum der Universitaet zu Koeln
50937 Koeln
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
University Hospital Tuebingen
72076 Tuebingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Banner MD Anderson Cancer Center
85234 Gilbert
United StatesRekrutierend» Google-Maps
Regeneron Study Site
85724-5024 Tucson
United StatesAbgeschlossen» Google-Maps
The Angeles Clinic
90025 Los Angeles
United StatesAbgeschlossen» Google-Maps
University of Southern California (USC)
90033 Los Angeles
United StatesRekrutierend» Google-Maps
Stanford Cancer Institute, Stanford Medicine at Stanford University
94304 Palo Alto
United StatesRekrutierend» Google-Maps
University Of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
94143-0981 San Francisco
United StatesAbgeschlossen» Google-Maps
George Washington University School of Medicine and Health Sciences
20037 Washington
United StatesRekrutierend» Google-Maps
University of Florida Health
032608 Gainesville
United StatesAbgeschlossen» Google-Maps
Sylvester Comprehensive Cancer Center
33136 Miami
United StatesAbgeschlossen» Google-Maps
Miami Cancer Institute at Baptist Health, Inc.
33176 Miami
United StatesRekrutierend» Google-Maps
University of South Florida (USF) - H. Lee Moffitt Cancer Center and Research Institute
33612 Tampa
United StatesRekrutierend» Google-Maps
Regeneron Study Site
40202 Louisville
United StatesAbgeschlossen» Google-Maps
Regeneron Study Site
21287 Baltimore
United StatesAbgeschlossen» Google-Maps
Massachusetts General Cancer Center
02114 Boston
United StatesRekrutierend» Google-Maps
Dana Farber/Harvard Cancer Center
02215 Boston
United StatesRekrutierend» Google-Maps
Michigan Medicine- University of Michigan
48109 Ann Arbor
United StatesRekrutierend» Google-Maps
University of Missouri Health Care - University Physicians - Medicine Specialty Clinic
65212 Columbia
United StatesRekrutierend» Google-Maps
Washington University in Saint Louis
63110 Saint Louis
United StatesRekrutierend» Google-Maps
Nebraska Methodist Hospital
68114 Omaha
United StatesRekrutierend» Google-Maps
Memorial Sloan Kettering
07920 Basking Ridge
United StatesAktiv, nicht rekrutierend» Google-Maps
Memorial Sloan Kettering
07748 Middletown
United StatesAktiv, nicht rekrutierend» Google-Maps
Memorial Sloan Kettering
07645 Montvale
United StatesAktiv, nicht rekrutierend» Google-Maps
Memorial Sloan Kettering
08903 New Brunswick
United StatesAktiv, nicht rekrutierend» Google-Maps
Memorial Sloan Kettering
11725 Commack
United StatesAktiv, nicht rekrutierend» Google-Maps
Memorial Sloan Kettering
10604 Harrison
United StatesAktiv, nicht rekrutierend» Google-Maps
Memorial Sloan Kettering Cancer Center
10065 New York
United StatesAktiv, nicht rekrutierend» Google-Maps
Memorial Sloan Kettering
11553 Uniondale
United StatesAktiv, nicht rekrutierend» Google-Maps
Regeneron Research Site
45267 Cincinnati
United StatesAbgeschlossen» Google-Maps
The Ohio State University
43230 Gahanna
United StatesRekrutierend» Google-Maps
Penn State Hershey Children's Hospital
17025 Hershey
United StatesRekrutierend» Google-Maps
University of Pennsylvania
19104 Philadelphia
United StatesRekrutierend» Google-Maps
Sarah Cannon Research Institute - Tennessee Oncology
37203 Nashville
United StatesRekrutierend» Google-Maps
Texas Oncology - Baylor Charles A. Simmons Cancer Center
75246 Dallas
United StatesAbgeschlossen» Google-Maps
UT Southwestern Medical Center
75390 Dallas
United StatesRekrutierend» Google-Maps
University Of Virginia Health System
22908 Charlottesville
United StatesRekrutierend» Google-Maps
The Border Cancer Hospital Dispensary - Albury Wodonga Regional Cancer Centre
2640 Albury
AustraliaRekrutierend» Google-Maps
Coffs Harbour Health Campus
2450 Coffs Harbour
AustraliaAktiv, nicht rekrutierend» Google-Maps
Central Coast Cancer Centre-Gosford and Wyong Hospitals
2250 Gosford
AustraliaRekrutierend» Google-Maps
North Shore Private Hospital
2065 St Leonards
AustraliaRekrutierend» Google-Maps
Cancer Care Associates (CCA) Riverina Cancer Care Centre (RCCC)
2650 Wagga Wagga
AustraliaRekrutierend» Google-Maps
Illawarra Cancer Care Centre (ICCC)
2500 Wollongong
AustraliaRekrutierend» Google-Maps
Wide Bay Hospital and Health Service - Cancer Care Services
4670 Bundaberg
AustraliaRekrutierend» Google-Maps
The Royal Brisbane and Women's Hospital
4029 Herston
AustraliaRekrutierend» Google-Maps
Genesis Care Tugun - John Flynn Private Hospital
4224 Tugun
AustraliaRekrutierend» Google-Maps
Wide Bay Hospital and Health Service - Cancer Care Services - Hervey Bay
4655 Urraween
AustraliaRekrutierend» Google-Maps
Princess Alexandra Hospital
4102 Woolloongabba
AustraliaRekrutierend» Google-Maps
Ashford Cancer Centre Research-Adelaide Cancer Centre
5037 Kurralta Park
AustraliaRekrutierend» Google-Maps
Royal Hobart Hospital-Hobart Hospital
7000 Hobart
AustraliaRekrutierend» Google-Maps
Olivia Newton -John Cancer Wellness & Research Centre
3084 Heidelberg
AustraliaRekrutierend» Google-Maps
Peter Maccallum Cancer Centre (PMCC)
3000 Melbourne
AustraliaRekrutierend» Google-Maps
Sir Charles Gairdner Hospital
6009 Nedlands
AustraliaRekrutierend» Google-Maps
Liverpool Cancer Therapy Center
2170 Liverpool
AustraliaRekrutierend» Google-Maps
University of New South Wales (UNSW) - Liverpool Hospital - Liverpool Cancer Therapy Centre
2170 Liverpool
AustraliaRekrutierend» Google-Maps
The Townsville Hospital and Health Service
4814 Townsville
AustraliaRekrutierend» Google-Maps
Universitair Ziekenhuis Leuven Gasthuisberg Campus
3000 Leuven
BelgiumRekrutierend» Google-Maps
Cliniques Universitaires Saint-Luc
1200 Bruxelles
BelgiumRekrutierend» Google-Maps
Fundacao Sao Francisco Xavier - Hospital Marcio Cunha (HMC) - Unidade I
35160-158 Ipatinga
BrazilRekrutierend» Google-Maps
Fundacao Pio XII - Hospital de Cancer de Barretos
90610-000 Barretos
BrazilRekrutierend» Google-Maps
Instituto Nacional de Cancer Jose Alencar Gomes da Silva ¿ INCA
20220-410 Santo Cristo
BrazilRekrutierend» Google-Maps
Hospital Sao Vicente de Paulo (HSVP)
99010-080 Passo Fundo
BrazilRekrutierend» Google-Maps
Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
90610-000 Porto Alegre
BrazilRekrutierend» Google-Maps
Centro De Novos Tratamentos Itajai
88301-220 Itajai
BrazilRekrutierend» Google-Maps
Centro Oncologico Mogi das Cruzes
08730-500 Mogi das Cruzes
BrazilRekrutierend» Google-Maps
Hospital das Clinicas da Faculdade de Medician de Ribeirao Preto FMRP USP
14049-900 Ribeirao Preto
BrazilRekrutierend» Google-Maps
Ynova pesquisa clinica
88020-210 Florianopolis
BrazilRekrutierend» Google-Maps
Instituto do Cancer do Estado de Sao Paulo - ICESP
05403-000 Sao Paulo
BrazilRekrutierend» Google-Maps
University Health Network- Princess Margaret Cancer Center
M5G 2M9 Toronto
CanadaRekrutierend» Google-Maps
Centre Hospitalier Universitaire (CHU) de Dijon - Hopital du Bocage
21079 Dijon
FranceRekrutierend» Google-Maps
Hopital Saint Andre - CHU de Bordeaux
33604 Bordeaux
FranceRekrutierend» Google-Maps
Hopital Ambroise Pare
92100 Boulogne Billancourt
FranceRekrutierend» Google-Maps
Centre Hospitalier Universitaire De Grenoble- Hopital Albert Michallon
38700 La Tronche
FranceRekrutierend» Google-Maps
Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez
59037 Lille
FranceRekrutierend» Google-Maps
Centre Leon-Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est (CRCL)
69008 Lyon
FranceRekrutierend» Google-Maps
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hopital Hotel Dieu
44093 Nantes
FranceRekrutierend» Google-Maps
Centre Hospitalier Universitaire de Nice,Hopital l Archet
06202 Nice
FranceRekrutierend» Google-Maps
Hospital Saint-Louis - APHP
75475 Paris Cedex 10
FranceRekrutierend» Google-Maps
CIC Cochin Pasteur, Hopital Cochin
7504 Paris
FranceRekrutierend» Google-Maps
Centre Hospitalier Lyon Sud
69495 Pierre Benite Cedex
FranceRekrutierend» Google-Maps
Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle
76031 Rouen cedex
FranceRekrutierend» Google-Maps
Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
94805 Villejuif Cedex
FranceRekrutierend» Google-Maps
University of Athens - Hospital of Venereology Dermatology Diseases Andreas Syggros
16121 Athens
GreeceRekrutierend» Google-Maps
Office of Dr. Aimilios Lallas MD
546 23 Thessaloniki
GreeceRekrutierend» Google-Maps
St. Vincent's University Hospital
DO4 YN63 Dublin
IrelandRekrutierend» Google-Maps
University College Cork-Cork University Maternity Hospital
Cork
IrelandRekrutierend» Google-Maps
University Hospital Galway
H91 YR71 Galway
IrelandRekrutierend» Google-Maps
Policlinico S.Orsola-Malpighi U.O. Dermatologia - University of Bologna
40138 Bologna
ItalyRekrutierend» Google-Maps
Universita di Firenze - Azienda Sanitaria Firenze
50125 Firenze
ItalyRekrutierend» Google-Maps
IRCCS-Istituto Europeo di Oncologia
20141 Milan
ItalyRekrutierend» Google-Maps
U.O.S.C Di Oncologia Medica E Terapie Innovative
43100 Napoli
ItalyRekrutierend» Google-Maps
A. Gemelli University Hospital, Catholic University of the Sacred Heart
00168 Rome
ItalyRekrutierend» Google-Maps
IRCCS Istituto Clinico Humanitas
20089 Rozzano
ItalyRekrutierend» Google-Maps
AOU Citta della Salute e della Scienza di Torino
10126 Torino
ItalyRekrutierend» Google-Maps
Sapporo Medical University Hospital
060-8543 Sapporo
JapanRekrutierend» Google-Maps
Shizuoka Cancer Center - Oncology
411-8777 Nagaizumi-Cho
JapanRekrutierend» Google-Maps
National Cancer Center Hospital - Gastrointestinal Oncology
104-0045 Chuo-ku
JapanRekrutierend» Google-Maps
Niigata Cancer Center Hospital
951-8566 Niigata
JapanRekrutierend» Google-Maps
Osaka International Cancer Institute - Clinical Oncology
541-8567 Osaka
JapanRekrutierend» Google-Maps
Palmerston North Hospital
4410 Palmerston North
New ZealandRekrutierend» Google-Maps
Narodowy Instytut Onkologii im. Marii Sk¿odowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach
44-102 Gliwice
PolandRekrutierend» Google-Maps
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
20-090 Warszawa
PolandRekrutierend» Google-Maps
State Healthcare Institution Oncology Dispensary 2 Ministry of Healthcare of Krasnodar Region
354057 Sochi
Russian FederationAktiv, nicht rekrutierend» Google-Maps
SBHI of Stavropol Region Pyatigorsk Interdistrict Oncology Dispensary
357502 Pyatigorsk
Russian FederationAktiv, nicht rekrutierend» Google-Maps
Regeneron Study Site
455001 Magnitogorsk
Russian FederationAbgeschlossen» Google-Maps
N.N.Blokhin Cancer Research Center
33756 Moscow
Russian FederationAktiv, nicht rekrutierend» Google-Maps
Regeneron Research Site
644013 Omsk
Russian FederationAbgeschlossen» Google-Maps
Federal State Budgetary Institution Rostov Research Institute of Oncology of the Ministry of Healthcare of the Russian Federation
344037 Rostov-Na-Donu
Russian FederationAktiv, nicht rekrutierend» Google-Maps
Regeneron Study Site
198255 Saint Petersburg
Russian FederationAbgeschlossen» Google-Maps
Hospital Universitari Vall d'Hebron
08035 Barcelona
SpainRekrutierend» Google-Maps
Hospital Universitario Fundacion Alcorcon
28922 Alcorcon
SpainRekrutierend» Google-Maps
Hospital Universitario de Torrejon
28850 Torrejon de Ardoz
SpainRekrutierend» Google-Maps
Catalan institute of Oncology Badalona
8916 Badalona
SpainRekrutierend» Google-Maps
Hospital Clinic de Barcelona - Institut Clinic de Malalties Hematologiques i Oncologiques (ICMHO)
08036 Barcelona
SpainRekrutierend» Google-Maps
Genesis Care hospital San Francisco de Asis
28002 Madrid
SpainRekrutierend» Google-Maps
Hospital General Universitario Gregorio Maranon (HGUGM)
28007 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario 12 de Octubre-Centro de Actividades Ambulatorias
28041 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario Puerta de Hierro de Majadahonda
28222 Majadahonda
SpainRekrutierend» Google-Maps
Hospital Clinico Universitario de Salamanca
37007 Salamanca
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen Macarena-merge
41009 Sevilla
SpainRekrutierend» Google-Maps
Instituto Valenciano de Oncología
46009 Valencia
SpainRekrutierend» Google-Maps
Hospital Universitario y Politecnico La Fe-merge
46026 Valencia
SpainRekrutierend» Google-Maps
Derriford Hospital
PL6 8DH Plymouth
United KingdomRekrutierend» Google-Maps
University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre (BHOC) - Bristol Cancer Institute
BS2 8ED Bristol
United KingdomRekrutierend» Google-Maps
Velindre NHS Trust, Velindre Cancer Centre
CF14 2TL Cardiff
United KingdomRekrutierend» Google-Maps
The Lothian University Hospitals NHS Lothian - Western General Hospital (WGH)
EH4 2XU Edinburgh
United KingdomRekrutierend» Google-Maps
Beatson West of Scotland Cancer Centre - Greater Glasgow Health Board
G12 0YN Glasgow
United KingdomRekrutierend» Google-Maps
St George's Hospital - St George's University Hospitals NHS Foundation Trust
SW17 0QT London
United KingdomAbgeschlossen» Google-Maps
The Christie - The Christie NHS Foundation Trust
M20 4QL Manchester
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

Cemiplimab is a monoclonal antibody. Antibodies are proteins naturally found in the blood. A

monoclonal antibody is a special antibody that is manufactured as a medication to target

specific proteins in the body that may be involved in cancer. Cemiplimab works by blocking

programmed death-1 (PD-1), a cell receptor on immune cells. By blocking PD-1, it is expected

that the immune cells will attack cancer cells.

The study is being conducted in participants that have had surgery and radiation therapy for

a type of skin cancer called cutaneous squamous cell cancer, and who have a risk that this

cancer may come back.

The main purpose of the study is to determine if cemiplimab will prevent cutaneous squamous

cell cancer (CSCC) from returning after surgery and radiation. Currently, we know that

certain types of CSCC have a high chance of coming back after surgery and radiation. At this

time, there is no approved treatment to give patients after surgery and radiation to prevent

high-risk CSCC from coming back. We are investigating if the addition of cemiplimab will

decrease the chance of these high-risk cancers coming back.

The study will also investigate if cemiplimab may help participants live for longer.

The study has two parts. Part 1: participants will receive every 3 weeks via intravenous

infusion (drip into a vein) either cemiplimab (study drug) or placebo (similar to the study

drug but without active medicine). After 12 weeks of treatment, cemiplimab or placebo will be

given every 6 weeks. Part 1 of the study includes a screening period (up to 28 days), a

treatment period (approximately 48 weeks), an end of treatment visit (approximately 30 days

after completion of study drug treatment period) and a post-treatment follow-up period

(approximately up to 5 years or until skin cancer returns or the study ends).

Part 2 of the study is optional and provides the participant with the option to receive

cemiplimab if the cancer comes back if the participant was initially receiving placebo. There

is no placebo in Part 2 of the study. If the cancer comes back, the study doctor will discuss

with participants if they are eligible to participate in the optional part 2 of the study.

Part 2 of the study includes a brief screening period, a treatment period (approximately 96

weeks) and an end of treatment visit (approximately 30 days after the completion of the study

drug treatment period).

Ein-/Ausschlusskriterien

Key Inclusion Criteria:

- For Japan only, men and women ≥21 years old

- Patient with resection of pathologically confirmed CSCC (primary CSCC lesion only, or

primary CSCC with nodal involvement, or CSCC nodal metastasis with known primary CSCC

lesion previously treated within the draining lymph node echelon), with macroscopic

gross resection of all disease

- High risk CSCC, as defined in the protocol

- Completion of curative intent post-operative radiation therapy (RT) within 2 to 10

weeks of randomization

- Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1

- Adequate hepatic, renal, and bone marrow function as defined in the protocol

Key Exclusion Criteria:

- Squamous cell carcinomas (SCCs) arising in non-cutaneous sites as defined in the

protocol

- Concurrent malignancy other than localized CSCC and/or history of malignancy other

than localized CSCC within 3 years of date of randomization as defined in the protocol

- Patients with hematologic malignancies (note: patients with chronic lymphocytic

leukemia (CLL) are not excluded if they have not required systemic therapy for CLL

within 6 months of enrollment)

- Patients with history of distantly metastatic CSCC (visceral or distant nodal), unless

the disease-free interval is at least 3 years (regional nodal involvement of disease

in draining lymph node basin that was resected and radiated prior to enrollment will

not be exclusionary)

- Ongoing or recent (within 5 years of randomization date) evidence of significant

autoimmune disease that required treatment with systemic immunosuppressive treatments,

which may suggest risk for immune-related adverse events (irAEs). The following are

not exclusionary: vitiligo, childhood asthma that has resolved, type 1 diabetes,

residual hypothyroidism that required only hormone replacement, or psoriasis that does

not require systemic treatment.

- Has had prior systemic anti-cancer immunotherapy for CSCC

Note: Other protocol defined Inclusion/Exclusion criteria apply

Studien-Rationale

Primary outcome:

1. DFS defined as time from randomization to the first documented disease recurrence (local, regional and/or distant); or death due to any cause. (Time Frame - Up to 54 months):
For patients who do not have a tumor recurrence or death, DFS will be censored on the date of last disease assessment.



Secondary outcome:

1. Overall survival (OS), defined as time from randomization to the date of death. A patient who has not died will be censored on the last known date as alive. (Time Frame - Up to 78 months)

2. FFLRR defined as time from randomization to the date of first locoregional recurrence (LRR). Patients who died without a preceding LRR will be censored on the date of death. (Time Frame - Up to 54 months):
For patients who do not have a LRR or death, FFLRR will be censored on the date of last disease assessment.

3. Freedom from distant recurrence (FFDR), defined as time from randomization to the date of first distant recurrence (DR). Patients who died without a preceding DR will be censored on the date of death. (Time Frame - Up to 54 months):
For patients who do not have a DR or death, FFDR will be censored on the date of last disease assessment.

4. Cumulative occurrence of second primary cutaneous squamous cell carcinoma tumor (SPTs) for each patient from randomization to occurrence of first primary endpoint event or end of study. (Time Frame - Up to 54 months)

5. Incidence and severity of treatment-emergent adverse events (TEAE) (Time Frame - Up to 78 months)

6. Incidence of deaths (Time Frame - Up to 78 months)

7. Incidence of laboratory abnormalities (Time Frame - Up to 78 months)

8. Cemiplimab concentrations in serum (Time Frame - Up to 78 months)

9. Anti-drug antibodies (ADA) in serum (Time Frame - Up to 78 months)

Studien-Arme

  • Experimental: Cemiplimab
  • Placebo Comparator: Placebo

Geprüfte Regime

  • Cemiplimab (REGN2810 / Libtayo / ):
    Intravenous (IV) infusion over 30 minutes
  • Placebo:
    Intravenous (IV) infusion over 30 minutes

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.